Updated Hepatitis C Care and Treatment Guidelines Published in Hepatology

The latest updated U.S. recommendations for hepatitis C testing, management, and treatment, compiled by an expert panel of members of the American Association for the Study of Liver Diseases (AASLD) and partner organizations, have been published in the June 25 advance online edition of Hepatology, the AASLD's professional journal.

First issued in 2014, the guidance includes recommendations on all aspects of HIV care, including the latest evidence-based guidelines for the use of direct-acting antiviral agents.

These agents -- usually used in interferon-free combination regimens taken for 12 or 24 weeks -- can now cure more than 90% of chronic hepatitis C patients, including those previously considered difficult-to-treat such as people with advanced liver cirrhosis, prior interferon non-responders, HIV/HCV coinfected people, and liver transplant recipients.

Below is a recent news release by Hepatology publisher Wiley announcing the published guidance. The full guidance is available for free online through Wiley or the dedicated website www.hcvguidelines.org.

AASLD Updates Guidance for Use of Hepatitis C Drugs

June 25, 2015 -- The American Association for the Study of Liver Diseases (AASLD), in partnership with the Infectious Diseases Society of America (IDSA) and in collaboration with the International Antiviral Society-USA (IAS-USA), created online Recommendations for Testing, Managing, and Treating Hepatitis C in 2014 to aid practitioners treating patients infected with hepatitis C virus (HCV). Now an update to the Guidance, with a summary of recommendations regarding treatment with direct-acting antiviral drugs, is published in the AASLD journal, Hepatology.

HCV is a blood-borne virus that infects the liver and may lead to cirrhosis or liver cancer (hepatocellular carcinoma). In the past 25 years HCV has gone from an undiagnosed disease to an epidemic level, with the World Health Organization (WHO) estimating that up to 150 million people worldwide live with chronic disease.

In the U.S., close to 30,000 new acute cases were reported in 2013 and 2.7 million Americans have chronic HCV according to the Centers for Disease Control and Prevention (CDC). "The good news is that HCV is now on the cusp of being a curable disease for the millions of Americans, many of whom are undiagnosed," says Dr. Gary Davis, President of MedLogician Consulting and co-chair of the AASLD/IDSA HCV Guidance writing panel. "The web-based Guidance document is an easy-to-use resource for practitioners treating HCV patients with novel antivirals."

A panel of 26 hepatologists and infectious diseases specialists and a patient advocate developed the original consensus recommendations that include:

• HCV testing details and linkage to care
• Recommendations for initial treatment of HCV infection in patients starting treatment
• Retreatment information in persons in whom prior therapy has failed
• Unique patient populations data

"The Guidance is a living document that will continually be updated with evidence-based advice about how to best use the next generation of direct-acting antivirals and other treatment options," comments Dr. Keith Lindor from the Arizona State University and President-elect of AASLD. "Our role as associations of researchers and clinicians is to provide key information in the appropriate format to patients and those who care for them."

Practitioners involved with treating patients with liver disease may access the Guidance, including new updates, atwww.HCVGuidelines.org.

7/3/15

Reference

AASLD/IDSA Hepatitis C Guidance Panel. Hepatitis C Guidance: AASLD-IDSA Recommendations for Testing, Managing, and Treating Adults Infected with Hepatitis C Virus. Hepatology. June 25, 2015 (Epub ahead of print).

Other Source

Wiley. AASLD Updates Guidance for Use of Hepatitis C Drugs. News release. June 25, 2015.